Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events Article

cited authors

  • Guo, Mengni; VanderWalde, Ari M.; Yu, Xinhua; Vidal, Gregory A.; Tian, G. Gary

Publication Date

  • November 18, 2022

webpage

published in

category

keywords

  • Best objective response
  • Immunotherapy discontinuation
  • Overall survival
  • Progression-free survival

start page

  • 686

end page

  • 693

volume

  • 23

issue

  • 8